Compare Of Clinical Practice Guidelines For The Assessment And Management Of Cutaneous Melanoma (Literature Review).
AbstractCurrently, there has been an increasing incidence of melanoma cancer in Iran, especially among the young population, which has led to increased mortality, disability and disablement mostly due to disease and treatment complications. New treatments such as targeted therapy are extremely costly, and their results are not clear. The objective of this study is to review different current guidelines that management the cutaneous melanoma cancer and discuss the differences in the various phases of patient assessment (prevention, risk factors, genetic assessment, clinical diagnosis, biopsy, staging, treatment and follow-up, pediatric Melanoma, melanoma during pregnancy, and necessity of social and mental support for melanoma patients). Then, with aid to the results, in the next step, we are going to prepare the national guidelines for the management of cutaneous melanoma in accordance with Iranian conditions.
2. clinical practice guidelines for the management of melanoma in Australia and new Zealand:(update). 2008.
3. nova scotia cancer care: Guidelines for the Management of Malignant Melanoma:(update). 2013.
4. Guidelines of care for the management of primary cutaneous melanoma (the American Academy of Dermatology). 2011.
5. AHRQ: Agency for healthcare research and quality. 2011.
6. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 2015.
7. Evidence-based Clinical Practice Guideline: Treatment of Cutaneous Melanoma (American society of plastic surgeons). 2007.
8. NICE guideline: assessment and management of melanoma: (update). 2018.
9. NCCN guideline: clinical practice guideline in oncology melanoma: (Update). 2018.
10. Cheng L, Lopez-Beltran A, Massari F, MacLennan GT, Montironi R. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2018;31(1):24-38.